Related Experiment Video

Updated: Jun 24, 2026

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump
09:04

A Modeling and Simulation Method for Preliminary Design of an Electro-Variable Displacement Pump

Published on: June 1, 2022

Humanitarian Use Device and Humanitarian Device Exemption regulatory programs: pros and cons

Daniel Maxwell Bernad1

  • 1Faculty of Medicine, University of Ottawa, Ontario, Canada. dmbernad@gmail.com

Expert Review of Medical Devices
|March 21, 2009
PubMed

Insights

The US Food and Drug Administration's Humanitarian Use Device (HUD) and Humanitarian Device Exemption (HDE) program offers benefits but also presents challenges for rare disease treatments. This study explores its advantages, disadvantages, and future device prospects.

Area of Science:

  • Medical device regulation
  • Rare disease therapeutics
  • Health policy

Background:

  • The US Food and Drug Administration (FDA) established the Humanitarian Use Device (HUD) and Humanitarian Device Exemption (HDE) program over a decade ago.
  • The program aims to incentivize medical device firms to develop treatments for rare diseases.
  • Limited peer-reviewed research exists on the effectiveness and practicalities of the HUD/HDE program.

Purpose of the Study:

  • To analyze the differences between the HUD/HDE regulatory pathway and the standard system.
  • To evaluate the potential benefits and drawbacks of the HUD/HDE program for device manufacturers.
  • To forecast which humanitarian devices may reach the market in the next five years.

Main Methods:

  • Conducted 40 semistructured interviews with stakeholders from firms that obtained HDE approval.
  • Interviewees represented approximately 49% of firms with successful HDE-approved products.
  • Gathered primary data on the experiences and perspectives of companies navigating the HUD/HDE program.

Main Results:

  • Launching humanitarian devices involves short-term financial gains but can lead to long-term financial drains.
  • Stakeholders provided insights into the practical challenges and rewards of the HUD/HDE program.
  • The study identified key factors influencing the success and challenges of humanitarian device development.

Conclusions:

  • The HUD/HDE program presents a complex regulatory landscape with both advantages and disadvantages for rare disease device development.
  • Informed decision-making for sponsors is crucial for successful product development in this area.
  • The findings aim to encourage further development of treatments for rare diseases through the HUD/HDE pathway.

Related Concept Videos

Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Standards of Care II01:19

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
PPE Use in Healthcare Settings II: Doffing01:10

PPE Use in Healthcare Settings II: Doffing

The sequence of removing or doffing PPE starts with the gloves, as they are the most contaminated. Next is removal of the face shield or goggles, as they would interfere with removing other PPE. Then remove the gown, followed by the mask or respirator. Perform hand hygiene between steps if hands become contaminated and immediately after removing all PPE. Generally, the outside front and sleeves of the isolation gown, the goggles or the mask, the respirator, and the face shield are contaminated.
Hazard Analysis and Critical Control Points (HACCP)01:30

Hazard Analysis and Critical Control Points (HACCP)

Hazard Analysis and Critical Control Points (HACCP) is a science-based, preventive system used globally to ensure food safety by identifying, evaluating, and controlling biological, chemical, and physical hazards throughout food production. Originally developed by NASA and the Pillsbury Company for astronaut food, HACCP is now a core component of the Codex Alimentarius.HACCP operates on prerequisite programs—such as Good Manufacturing Practices (GMPs), sanitation procedures, and supplier...